<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469492</url>
  </required_header>
  <id_info>
    <org_study_id>1602017151</org_study_id>
    <nct_id>NCT03469492</nct_id>
  </id_info>
  <brief_title>Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose</brief_title>
  <official_title>Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose: an Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether longer-term improvement of glycemic control in poorly controlled
      diabetes patients with a 12-week intensified insulin treatment regimen will lead to decreased
      polyol pathway activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polyol pathway activity will decrease in diabetic individuals who undergo intensification of
      their insulin treatment regimens as reflected by lower baseline brain intracellular fructose
      levels and higher intracellular glutathione levels. Furthermore, following longer-term
      improved glycemic control, patients may also have down-regulation of the pathway as reflected
      by decreased production of intracellular fructose in response to hyperglycemic clamp.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1C</measure>
    <time_frame>12 weeks</time_frame>
    <description>reduction of A1C levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gluthathione</measure>
    <time_frame>0 weeks</time_frame>
    <description>baseline MRS scan to measure gluthathione</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gluthathione</measure>
    <time_frame>12 weeks</time_frame>
    <description>MRS scan to measure gluthathione</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma glucose</measure>
    <time_frame>0 weeks</time_frame>
    <description>MRS scan to measure plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>MRS scan to measure plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma fructose</measure>
    <time_frame>0 weeks</time_frame>
    <description>MRS scan to measure plasma fructose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma fructose</measure>
    <time_frame>12 weeks</time_frame>
    <description>MRS scan to measure plasma fructose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma insulin</measure>
    <time_frame>0 weeks</time_frame>
    <description>MRS scan to measure plasma insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>MRS scan to measure plasma insulin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Optional Hyperglycemic Clamp</measure>
    <time_frame>upon enrollement</time_frame>
    <description>Hyperglycemic clamp administered to measure glucose levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperglycaemia (Diabetic)</condition>
  <arm_group>
    <arm_group_label>type 2 diabetes mellitus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with type 2 diabetes on insulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>type 1 diabetes mellitus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with type 1 diabetes on insulin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.</description>
    <arm_group_label>type 2 diabetes mellitus</arm_group_label>
    <arm_group_label>type 1 diabetes mellitus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise</intervention_name>
    <description>Exercise in accordance to the guidelines established by the American Diabetes Association.</description>
    <arm_group_label>type 2 diabetes mellitus</arm_group_label>
    <arm_group_label>type 1 diabetes mellitus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary counseling</intervention_name>
    <description>Dietary counseling in accordance to the guidelines established by the American Diabetes Association.</description>
    <arm_group_label>type 2 diabetes mellitus</arm_group_label>
    <arm_group_label>type 1 diabetes mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  15 Type 2 DM subjects with HbA1C &gt; 7.5%

          -  15 Type 1 DM subjects with HbA1C &gt; 7.5%

          -  Age 18-60

          -  BMI ≥18 kg/m2

          -  Weight ≤ 285 pounds

        Exclusion Criteria:

          -  Creatinine &gt; 1.5 mg/dL, Hgb &lt; 10 mg/dL, ALT &gt; 2.5 X ULN,

          -  untreated thyroid disease,

          -  uncontrolled hypertension,

          -  known neurological disorders,

          -  untreated psychiatric disorders,

          -  malignancy,

          -  bleeding disorders,

          -  current or recent steroid use in last 3 months,

          -  illicit drug use;

          -  for women: pregnancy, actively seeking pregnancy, or breastfeeding; inability to enter

          -  MRI/MRS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section of Endocrinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janice Hwang, MD</last_name>
    <phone>203-785-6222</phone>
    <email>Janice.hwang@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Sherwin, MD</last_name>
    <phone>203-785-4183</phone>
    <email>robert.sherwin@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Anylan Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Hwang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Janice Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

